Vizual Stocks works best vertically on mobile.
VizualStocks APIOperating KPI and segment definitions available for Tempus AI (TEM) through the VizualStocks API.
Potential future contract value included in Tempus Remaining TCV that depends on customers exercising discretionary opt-in purchases. It is an opportunity estimate within signed contract frameworks, not firm committed backlog or recognized revenue.
additionalPotentialFutureOptInsRevenue from licensing de-identified clinical and molecular data to pharmaceutical and biotechnology companies, AI-enabled clinical-trial matching, analytical services and Tempus's Next care-gap platform. Tempus renamed this product line Data and Applications in 2026, while the API retains the former Data and Services identifier.
dataAndServicesRevenueRevenue from Tempus oncology testing and Ambry hereditary testing, including molecular and anatomic pathology, inherited cancer-risk tests, and exome or genome profiling for rare conditions. Tempus renamed this product line Diagnostics in 2026, while the API retains the former Genomics identifier.
genomicsRevenueAnnual Insights revenue from customers that purchased the product in one year divided by annual Insights revenue from the same customer cohort in the following year. The rate captures expansion, contraction and customer loss within Tempus's data-licensing business rather than companywide recurring revenue.
netRevenueRetentionPotential value remaining under signed Tempus contracts after revenue already recognized, assuming all contractual options and discretionary opt-ins are exercised and no customer terminates early. It includes large strategic collaborations that may be fulfilled with products outside Data and Applications, so it is broader and less firm than GAAP remaining performance obligations.
remainingTotalContractValue